Literature DB >> 16403094

Polymorphic eruption of pregnancy: clinicopathology and potential trigger factors in 181 patients.

C M Rudolph1, S Al-Fares, S A Vaughan-Jones, R R Müllegger, H Kerl, M M Black.   

Abstract

BACKGROUND: Polymorphic eruption of pregnancy (PEP; synonym: pruritic urticarial papules and plaques of pregnancy) is the most common specific dermatosis of pregnancy. However, its clinical characterization is controversial and its pathogenesis uncertain.
OBJECTIVES: To evaluate clinical characteristics of and potential trigger factors for PEP in a large mixed ethnic population.
METHODS: A retrospective analysis of epidemiological, clinical, immunopathological and obstetric findings in 181 patients with PEP seen at two university-based dermatological hospitals in Graz, Austria, and London, U.K.
RESULTS: PEP mainly affected white (88%) primigravidae (70%) in late pregnancy (83%; mean +/- SD onset 34 +/- 5 weeks) or the immediate postpartum period (15%). The most commonly involved sites were the abdomen and proximal thighs (97%). Involvement of the whole skin, including the face, palms and soles, was only rarely observed. While pruritic urticarial papules and plaques were the main morphological features at disease onset (98%), more than one-half of the patients (51%) later developed polymorphous features including erythema, vesicles, and targetoid and eczematous lesions. Topical treatment with corticosteroids and emollients was sufficient to control symptoms in the majority of patients, and skin lesions resolved after a mean +/- SD of 4 +/- 3 weeks. Multiple gestation pregnancies were observed in 13% of cases, excessive maternal weight gain in 78%.
CONCLUSIONS: Our data confirm the benign, self-limiting nature of PEP and its favourable outcome for both the mother and the fetus. For the first time, we have documented a characteristic change in morphology with disease progression. The evidence of polymorphous clinical features in more than one-half of the patients favours the use of the term PEP. Multiple gestation pregnancies and excessive maternal weight gain, but not fetal weight and sex, were found to be significantly associated with PEP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403094     DOI: 10.1111/j.1365-2133.2005.06856.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

Review 1.  [The specific dermatoses of pregnancy].

Authors:  C M Ambros-Rudolph
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

Review 2.  [Specific dermatoses of pregnancy].

Authors:  C M Ambros-Rudolph; M Sticherling
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

3.  Polymorphic eruption of pregnancy presented with targetoid lesions: a report of two cases.

Authors:  Wararat Sirikudta; Narumol Silpa-Archa
Journal:  Case Rep Dermatol       Date:  2013-05-03

4.  Dermatoses of pregnancy - clues to diagnosis, fetal risk and therapy.

Authors:  Christina M Ambros-Rudolph
Journal:  Ann Dermatol       Date:  2011-08-06       Impact factor: 1.444

Review 5.  Pruritus in female patients.

Authors:  Julien Lambert
Journal:  Biomed Res Int       Date:  2014-03-10       Impact factor: 3.411

Review 6.  Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?

Authors:  Katja Woidacki; Ana Claudia Zenclussen; Frank Siebenhaar
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

7.  Pregnancy and skin.

Authors:  Rita V Vora; Rajat Gupta; Malay J Mehta; Arvind H Chaudhari; Abhishek P Pilani; Nidhi Patel
Journal:  J Family Med Prim Care       Date:  2014 Oct-Dec

8.  Polymorphic eruption of pregnancy developing postpartum: 2 case reports.

Authors:  Ellen Cathrine Pritzier; Carsten Sauer Mikkelsen
Journal:  Dermatol Reports       Date:  2012-06-06

9.  The dermatoses of pregnancy.

Authors:  Silonie Sachdeva
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

Review 10.  Gestational pemphigoid.

Authors:  Laura Huilaja; Kaarin Mäkikallio; Kaisa Tasanen
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.